Rocket Pharmaceuticals, Inc. Goodwill and Intangible Asset Impairment
Rocket Pharmaceuticals, Inc. (RCKT) reported Goodwill and Intangible Asset Impairment of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GoodwillAndIntangibleAssetImpairment · last filed 2025-02-27
- Rocket Pharmaceuticals, Inc. goodwill and intangible asset impairment for the quarter ending 2024-12-31 was $0.00.
- Rocket Pharmaceuticals, Inc. goodwill and intangible asset impairment for the quarter ending 2023-12-31 was $0.00.
- Rocket Pharmaceuticals, Inc. goodwill and intangible asset impairment for the quarter ending 2022-12-31 was $0.00.
- Rocket Pharmaceuticals, Inc. goodwill and intangible asset impairment for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Rocket Pharmaceuticals, Inc. goodwill and intangible asset impairment for fiscal 2023 was $574.00K.
- Rocket Pharmaceuticals, Inc. goodwill and intangible asset impairment for fiscal 2022 was $0.00.
- Rocket Pharmaceuticals, Inc. goodwill and intangible asset impairment for fiscal 2021 was $0.00.
| Period end | Goodwill and Intangible Asset Impairment 3 month | Goodwill and Intangible Asset Impairment 9 month | Goodwill and Intangible Asset Impairment 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $574.00K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $574.00K 10-Q · filed 2024-11-07 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |